Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.91 USD
-0.26 (-0.96%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $26.91 0.00 (0.00%) 7:36 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 1 - 20 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Appears Poised for Solid Uptake; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Wins FDA Approval; U.S. Launch Next Quarter; Raising PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Approval Decision Imminent; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Approval Decision Imminent; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine FDA Approval Decision Nears; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY23: Counting Down to the Ensifentrine/COPD PDUFA, Launch Prep Ongoing
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
MA Underscores Respiratory Asset Allure; New Debt Facility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Looks Like What GlaxoSmithKline Seeks: Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VRNA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Launch Readiness Ongoing; Fixed-Dose Combo; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3: Ensifentrine/COPD NDA Review Ongoing, Launch Prep Remains Near-Term Focus
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Commercial Positioning Investor Update Event Takeaways; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Investor Launch Day Highlights; Pre-Launch Preparations Underway
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A